GSK's RSV vaccine has received broader clearance from the FDA. Reports about other vaccines, including those from Moderna, indicate varying levels of regulatory progress and scrutiny. The status of Moderna's flu vaccine, in particular, is unclear, with some reports suggesting FDA refusal to review it and others indicating support from regulators.